The project "Genomic variation of cytomegalovirus (CMV) in congenitally infected infants" is linked to thematic project inserted into a master project entitled "Cytomegalovirus (CMV) vacines: reinfection and antigenic variation" supported by National Institute of Allergy and Infectious Diseases, (NIAID) [GRANT AWARD 2RO1 HD061959-07A2] to William J. Britt. The main objective is to define the diversity of viral genomes present in longitudinally collected samples of infants with congenital CMV infection from birth to up 6 years of age. The development of this project will be conducted in two phases. The initial phase will be conducted in Brazil and the following step in University of Massachusetts , USA. In this second phase, a high throughput ("deep sequencing") sequencing technology will be performed in saliva and urine from congenitally infected newborn infants to analyze CMV genome. Direct sequencing produces limited numbers of reads that map to HCMV reference sequences. Genome-wide deep sequencing of CMV in clinical specimens is required to analyze HCMV population diversity and dynamics in infected hosts. The use of this robust technology could allow to obtain strong evidences to confirm a mixed population of CMV in congenitally infected infants.
News published in Agência FAPESP Newsletter about the scholarship: